Liminatus Pharma, Inc. (LIMN:NASDAQ) closed at $2.97 on November 16, 2026, down 0.67% on the day. The stock trades 97.9% below its 52-week high of $141.50 and 23.5% above its 52-week low of $2.40. Over the past year, it lost 94.6%. Liminatus Pharma, Inc. is part of the Health Care sector.
In 252 trading sessions since November 14, 2025, LIMN closed higher on 99 days (39%). Its best day was February 3, 2026 (+87.39%) and its worst was February 11, 2026 (-52.62%). The stock moved 10% or more in a single session 38 times. It opened at least 5% above the previous day's high 4 times.
Liminatus Pharma, Inc. is pre-clinical stage biopharmaceutical company developing novel, immune-modulating cancer therapies. The Company's candidate IBA101, is a humanized anti CD47 monoclonal antibody. The next generation CD47 checkpoint inhibitor's initial indication is expected to be patients with advanced solid cancers including non-small cell lung cancer. The Company's vision is to develop a broad array of transformative therapies for cancer patients as a leading global biopharmaceutical company.
Find more stocks like LIMN with the Spikes, Gaps, Breakouts and Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.